QureBio, a company from Shanghai, China, that creates special antibody and protein medicines, has raised almost CNY 100 million (about $14 million) in Series C1 funding.
Efung Capital led the round.
The company plans to use the money to speed up its clinical trials and develop new antibody medicines.
Qure Biotechnology was founded in 2017. It is a biopharmaceutical company that focuses on researching and developing new antibody and protein medicines. They especially work on bispecific and multispecific antibodies to treat cancer, autoimmune diseases, and inflammation.
The company has created several special technology platforms to discover and improve antibodies. This helps them develop a pipeline of new drug candidates to meet important medical needs in China and around the world.
Q-1802 is a special antibody medicine targeting Claudin18.2 and PD-L1. It got approval to start clinical trials in China and the United States in March 2021. Most patients have been enrolled for the Phase II trial, and the company is getting ready to begin Phase III trials in China.
Q-1801 is a special antibody medicine targeting SIRPα and PD-L1. It has received approval to start clinical trials in China and the US and is ready to begin testing.
The PD-1 Antibody-Cytokine Fusion Candidate is a new type of medicine that works in two ways: it blocks the PD-1 checkpoint and also controls cytokines, which are important for the immune system. It shows promise for being both effective and safe.
This medicine targets a difficult area where bigger companies have faced challenges. QureBio is looking for partners to help speed up its development worldwide.
Read more- Dhruva Space Teams Up with France’s Sodern ArianeGroup to Advance Satellite Technology
